HHS Drug Pricing Program Flouts Constitution, Boehringer Says
By Brian Steele · June 20, 2024, 5:42 PM EDT
An "unprecedented" new Medicare price negotiation program deprives drugmakers of their constitutional rights and forces them to make declarations on issues of public concern that reflect poorly on them, Boehringer Ingelheim...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login